Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
27 Octobre 2023 - 2:00PM
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical
drug development company focused on advancing novel therapeutics
targeting retinal degenerative eye diseases that have significant
unmet medical needs, today announced that the two-year data from
the Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent STGD1
will be presented at the American Academy of Ophthalmology Annual
Meeting (AAO 2023) being held November 3 – November 6, 2023, in San
Francisco, CA.
Details of the presentation are as
follows: Title: A Phase 1b/2
Study of the Safety and Tolerability of Tinlarebant in Adolescent
Stargardt Subjects Session:
PA050 Date and Time:
Sunday, November 5, 2023; 3:57 PM to 4:04 PM
PST Location: Moscone Center,
San Francisco Presenting
Author: Dr. John Grigg, MBBS
About Tinlarebant (a/k/a
LBS-008)
Tinlarebant is a novel oral therapy that is
intended to reduce the accumulation of toxins in the eye that cause
STGD1 and contribute to GA, or advanced Dry Age-Related Macular
Degeneration (AMD). These toxins are byproducts of the visual
cycle, which is dependent on the supply of vitamin A (retinol) to
the eye. Tinlarebant works by reducing and maintaining levels of
serum retinol binding protein 4 (RBP4), the sole carrier protein
for retinol transport from the liver to the eye. By modulating the
amount of retinol entering the eye, Tinlarebant reduces the
formation of the toxins that cause STGD1 and contribute to GA.
Stargardt Disease (STGD1)
STGD1 is the most common inherited retinal
dystrophy (causing blurring or loss of central vision) in both
adults and children. The disease is caused by mutations in a
retina-specific gene (ABCA4) that results in massive accumulation
of toxic vitamin A byproducts (known as “bisretinoids”) in the
retina leading to retinal cell death and progressive loss of
central vision. The fluorescent properties of bisretinoids and the
development of retinal imaging systems have helped ophthalmologists
identify and monitor disease progression. Currently, there are no
FDA approved treatments for STGD1.
Importantly, STGD1 and GA, or advanced Dry AMD,
share a similar pathophysiology that is characterized by the
excessive accumulation of cytotoxic bisretinoids, retinal cell
death, and loss of vision. Vision loss occurs slowly, despite
peripheral expansion of “dead retina,” until the disease reaches
the center of the eye (the macula). Therefore, Belite Bio intends
to evaluate safety and efficacy of Tinlarebant in GA patients in
its Phase 3 PHOENIX study.
GA in advanced Dry Age-related Macular
Degeneration (Dry AMD)
Dry AMD is a leading cause of vision loss in
older adults. GA is the advanced stage of AMD. Currently, there are
no FDA approved, orally administered treatments for GA and no FDA
approved therapies for stages of Dry AMD other than GA. There are
an estimated 20 million AMD patients in the U.S. and over 196
million patients worldwide with an estimated global direct
healthcare cost of US $255 billion.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical
drug development company focused on advancing novel therapeutics
targeting retinal degenerative eye diseases that have significant
unmet medical needs, such as STGD1 and GA in advanced Dry AMD, in
addition to specific metabolic diseases. For more information,
follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at
www.belitebio.com.Important Cautions Regarding Forward
Looking Statements
This press release contains forward-looking
statements, including statements regarding Belite Bio’s advancement
of, and anticipated preclinical activities, and clinical
development . Actual results may differ materially from those
indicated in the forward-looking statements as a result of various
important factors, including but not limited to Belite Bio’s
ability to demonstrate the safety and efficacy of its drug
candidates; the clinical results for its drug candidates, which may
not support further development or regulatory approval; the content
and timing of decisions made by the relevant regulatory authorities
regarding regulatory approval of Belite Bio’s drug candidates; the
potential efficacy of Tinlarebant, as well as those risks more
fully discussed in the “Risk Factors” section in Belite Bio’s
filings with the U.S. Securities and Exchange Commission. All
forward-looking statements are based on information currently
available to Belite Bio, and Belite Bio undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as may be required by law.
Media and Investor Relations Contact:Jennifer
Wu ir@belitebio.comArgot belitebio@argotpartners.com
Belite Bio (NASDAQ:BLTE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Belite Bio (NASDAQ:BLTE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024